Asked by: Catherine McKinnell (Labour - Newcastle upon Tyne North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has conducted any impact assessments on the effect on the healthcare system in the UK of the UK leaving the EU.
Answered by Steve Barclay - Secretary of State for Environment, Food and Rural Affairs
The Government is committed to ensuring leaving the European Union is a success for the health and social care sector as well as the United Kingdom as a whole.
Impact Assessments, typically related to specific new primary legislation before Parliament, are narrowly defined. For example, the Government laid an impact assessment alongside the European Union (Withdrawal) Bill, which can be found on our website through the following link:
Civil servants conduct any Impact Assessments related to legislation as business as usual. All policy teams in my Department have conducted assessments of the implications of Brexit and continue to plan for all scenarios.
Asked by: Catherine McKinnell (Labour - Newcastle upon Tyne North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 March 2018 to Question 132059 on Mental Health Services: North East, in what format is the information requested held.
Answered by Jackie Doyle-Price
National Health Service statistics on beds is available at:
https://www.england.nhs.uk/statistics/statistical-work-areas/bed-availability-and-occupancy
This collection, KH03, collects the total number of available bed days and the total number of occupied bed days by consultant speciality.
Asked by: Catherine McKinnell (Labour - Newcastle upon Tyne North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer to 21 March 2018 to Question 133791, what the outcome was of recent discussions with the National Institute for Health and Care Excellence with reference to access to Orkambi for people with cystic fibrosis.
Answered by Steve Brine
The National Institute for Health and Care Excellence (NICE) has procedures in place to review published technology appraisal guidance to determine whether there is significant new evidence that might call for its guidance to be updated. Departmental officials have had a number of discussions with NICE concerning its appraisal of Orkambi for the treatment of cystic fibrosis and NICE next plans to review its guidance in July 2019, but will bring forward the review date if significant new evidence comes to light before that date that might affect its recommendations.
Asked by: Catherine McKinnell (Labour - Newcastle upon Tyne North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 March 2018 to Question 133793 on Cystic Fibrosis, what information his Department holds on the geographical spread in England of those people.
Answered by Steve Brine
No information is held by the Department on the geographical spread of people with cystic fibrosis in England. However, the UK Cystic Fibrosis Registry, sponsored and managed by the Cystic Fibrosis Trust, records data on consenting people with cystic fibrosis in England, Wales, Scotland and Northern Ireland. Publicly available information from the registry includes an interactive map showing the distribution of cystic fibrosis across the United Kingdom. The interactive map can be found at the following link:
Asked by: Catherine McKinnell (Labour - Newcastle upon Tyne North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect of the potential de-alignment with the EU’s Clinical Trials Regulation (CTR) on access to cancer treatments after the UK leaves the EU.
Answered by Jackie Doyle-Price
The Government values the strong collaborative partnerships that we have across the European Union in the areas of science, research and innovation, and as part of exit negotiations is working to ensure that we have the best possible environment in which to support the United Kingdom medical research sector and patient access to cross-border clinical trials after we leave the EU.
In the UK, the Medicines and Healthcare products Regulatory Agency, Health Research Authority, ethics services, National Institute for Health Research and the National Health Service have been working towards implementation of the new European Clinical Trials Regulation (CTR) since it was agreed in 2014. The application date of the CTR across the EU is yet to be set by the European Commission, but is expected to be in early 2020.
Whatever the outcome of the UK’s EU exit negotiations, the current regulatory approval legislation will stay in place until such time as any changes are needed, so there will be no interruption in UK clinical trials approval. The EU Withdrawal Bill will make the current UK clinical trials regulations (2004 2001/1031) that implement the clinical trials directive (2001/20/EC) operable on exit day and this is not contingent on any decision about whether the CTR will apply in the future.
Asked by: Catherine McKinnell (Labour - Newcastle upon Tyne North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the timetable is for the upcoming Green Paper on adult social care to publish recommendations; and what the timescale is for bringing forward legislative proposals as a result of that Green Paper.
Answered by Caroline Dinenage
The Government has committed to publishing a Green Paper by summer 2018, setting out its proposals for reform.
Ahead of the Green Paper’s publication, the Government is working with experts, stakeholders and people using care and support services, including for people suffering from dementia, to shape social care reform in the near and longer term.
Asked by: Catherine McKinnell (Labour - Newcastle upon Tyne North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the Green Paper on adult social care will look at short-term and long-term social care reforms for people with dementia.
Answered by Caroline Dinenage
The Government has committed to publishing a Green Paper by summer 2018, setting out its proposals for reform.
Ahead of the Green Paper’s publication, the Government is working with experts, stakeholders and people using care and support services, including for people suffering from dementia, to shape social care reform in the near and longer term.
Asked by: Catherine McKinnell (Labour - Newcastle upon Tyne North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with the National Institute for Health and Care Excellence on access to Orkambi for people with cystic fibrosis.
Answered by Steve Brine
Departmental officials regularly discuss a range of matters with colleagues in the National Institute for Health and Care Excellence, including the availability of Orkambi for the treatment of people with cystic fibrosis.
Asked by: Catherine McKinnell (Labour - Newcastle upon Tyne North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people suffer from cystic fibrosis in (a) Newcastle, (b) the north east of England and (c) England.
Answered by Steve Brine
This data is not available. However, cystic fibrosis is estimated to affect about 7,700 people in England (1 in 2,500 live births).
Asked by: Catherine McKinnell (Labour - Newcastle upon Tyne North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 1 March 2018 to Question 130615, when the review of the effect of debt and financial difficulties on people with mental health problems will be (a) completed and (b) published.
Answered by Jackie Doyle-Price
The Department continues to work with the Money and Mental Health Policy Institute and a range of stakeholders from the financial and debt advice sectors and the British Medical Association to undertake the review, which we will publish in due course.